The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.

Citi analyst Yigal Nochomovitz maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of ...

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...

New Found Gold Corp. ("New Found" or the "Company") (TSXV: NFG) (NYSE-A: NFGC) is pleased to announce the appointment of Dr.

Davis New York Venture Fund returned +17.51% in 2024. The fund has consistently grown wealth for shareholders since its ...

The First Trust Mid Cap Value AlphaDEX ETF (FNK) made its debut on 04/19/2011, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - Mid Cap Value category of the ...

Vanguard overtakes State Street as world's largest ETF provider, with VOO emerging as largest ETF by assets. Investors flock to cost-efficient, passive investing.

JP Morgan analyst Matthew Boss upgraded the rating for Bath & Body Works, Inc. BBWI from Neutral to Overweight and boosted ...

Highlights,CRISPR Therapeutics has seen price adjustments from financial firms, reflecting shifts in market expectations.,The ...